Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 5/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15267547 | 0.85 | PIM1 (0.56) | MPOSLC6A4PIM1PIM3TRIM24 | |
| SCHEMBL31188773 | 0.85 | PIM1 (0.56) | MPOSLC6A4PIM1PIM3TRIM24 | |
| SCHEMBL11476341 | 0.77 | LIPG (0.45) | MAPT | |
| SCHEMBL12811072 | 0.77 | TRIM24 (0.46) | MPOSLC6A4PIM1PIM3TRIM24 | |
| SCHEMBL13130755 | 0.77 | TRIM24 (0.46) | MPOSLC6A4PIM1PIM3TRIM24 | |
| SCHEMBL1424322 | 0.77 | KDM4E (0.51) | SLC6A4PIM1PIM3TRIM24TRIM33 | |
| SCHEMBL13715289 | 0.74 | HTR2A (0.69) | MPOSLC6A4TRIM24TRIM33HTR2A | |
| SCHEMBL8041051 | 0.74 | TRIM24 (0.43) | MPOSLC6A4PIM1PIM3TRIM24 | |
| SCHEMBL617128 | 0.73 | LIPG (0.55) | MAPT | |
| SCHEMBL29954763 | 0.72 | TRIM24 (0.70) | PIM1PIM3TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419430-A2 | NOVEL COMPOUNDS OF REVERSE-TURN MIMETICS, METHOD FOR MANUFACTURING THE SAME AND USE THEREOF | JW Pharmaceutical Corporation (KR) | 2012-02-22 | — | — | EP | claimed |
| US-20100267672-A1 | NOVEL COMPOUNDS OF REVERSE-TURN MIMETICS, METHOD FOR MANUFACTURING THE SAME AND USE THEREOF | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-21 | — | — | US | claimed |
| WO-2010120112-A2 | NOVEL COMPOUNDS OF REVERSE-TURN MIMETICS, METHOD FOR MANUFACTURING THE SAME AND USE THEREOF | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-21 | — | — | WO | claimed |
| EP-2419430-A2 | NOVEL COMPOUNDS OF REVERSE-TURN MIMETICS, METHOD FOR MANUFACTURING THE SAME AND USE THEREOF | JW Pharmaceutical Corporation (KR) | 2012-02-22 | — | — | EP | disclosed |
| US-20100267672-A1 | NOVEL COMPOUNDS OF REVERSE-TURN MIMETICS, METHOD FOR MANUFACTURING THE SAME AND USE THEREOF | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-21 | — | — | US | disclosed |
| WO-2010120112-A2 | NOVEL COMPOUNDS OF REVERSE-TURN MIMETICS, METHOD FOR MANUFACTURING THE SAME AND USE THEREOF | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267672-A1 | NOVEL COMPOUNDS OF REVERSE-TURN MIMETICS, METHOD FOR MANUFACTURING THE SAME AND USE THEREOF | MCL1, THPO, FLT3 | MPO 721/4885SLC6A4 4845/4885PIM1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.